10 analysts have shared their evaluations of Rhythm Pharmaceuticals RYTM during the recent three months, expressing a mix of bullish and bearish perspectives. The table below offers a condensed ...
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Free Report) – Investment analysts at HC Wainwright issued their FY2026 earnings per share estimates for Rhythm Pharmaceuticals in a research report ...
RYTM) released new topline data from its Phase 3 pediatrics trial evaluating one year of setmelanotide in patients aged two and below six years with Bardet-Biedl syndrome (BBS) or ...
Stifel Nicolaus analyst Paul Matteis maintained a Buy rating on Rhythm Pharmaceuticals (RYTM – Research Report) today and set a price target of $78.00. The company’s shares opened today at $47.95.
Given this risk, we thought we'd take a look at whether Rhythm Pharmaceuticals (NASDAQ:RYTM) shareholders should be worried about its cash burn. In this article, we define cash burn as its annual ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results